TXG
10x Genomics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 23 to Mar 24 ▼ 2 days of insider sells: $288.9K by 1 insider, avg $19.26
- May 22 to May 26 ▼ 2 days of insider sells: $1.4M by 3 insiders, avg $24.49
- Jun 16 to Jun 22 ▼ 2 days of insider sells: $1.2M by 2 insiders, avg $34.15
- Jun 30 ▲ 4 funds open new positions (13F)
- Aug 11 to Aug 14 ▼ 3 days of insider sells: $1.6M by 2 insiders, avg $57.61
- Aug 24 to Aug 26 ▼ 2 days of insider sells: $3.9M by 4 insiders, avg $63.16
- Sep 3 to Sep 9 ▼ 2 days of insider sells: $4.2M by 2 insiders, avg $63.72
- Sep 22 ▼ 2 insiders sell $2.5M at $81.22
- Sep 28 Argus Research initiates
- Nov 5 ▲ 10x Genomics reported Q3 2026 revenue of $150.7M (+1% YoY), slightly…
- Nov 5 ▲ Earnings: TXG Q3 2026 Earnings: EPS $-0.15 (+43.4% vs est)
- Nov 10 ▼ 1 insider sell $1.9M at $62.90
Signal stack
Where each data set points today.
- InsidersBEARISH
6 insiders sold $17.2M.
- InstitutionsMIXED
Q2 2026: 28 added (4 new), 23 trimmed or exited. Largest new: Point72 Asset Management, $71.0M, Jane Street Group $28.9M.
- AnalystsBULLISH
10 of 21 rate it Buy or better. Median target $65.00 (+17%).
- EstimatesFALLING
Current-quarter EPS estimate −$0.003 → −$0.040 over 90 days.
- Short sellersSTEADY
Short interest −2.0% to 12.47M shares. 4.1 days to cover, ≈9.5% of shares.
- TrendDOWNTREND
25% below its 50-day average.
- SocialQUIET
Crowd 42° (neutral) this week from 2 mentions: 0 bullish, 1 bearish. No setup is alerting.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| PRICE T ROWE ASSOCIATES INC /MD/ | DOUBLED | $174.0M |
| MORGAN STANLEY | ADD | $128.5M |
| CITADEL ADVISORS LLC | DOUBLED | $106.6M |
| Point72 Asset Management, L.P. | NEW | $71.0M |
| Nuveen, LLC | ADD | $43.1M |
| JANE STREET GROUP, LLC | NEW | $28.9M |
| HSBC HOLDINGS PLC | ADD | $20.3M |
| CAISSE DE DEPOT ET PLACEMENT DU QUEBEC | DOUBLED | $17.1M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
21 analystsPrice is inside the target range. Median implies +17%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 9, 2026 | JP Morgan MAINTAIN | Neutral |
| Nov 9, 2026 | Barclays MAINTAIN | Overweight |
| Nov 6, 2026 | UBS MAINTAIN | Neutral |
| Nov 6, 2026 | Citigroup MAINTAIN | Neutral |
| Nov 6, 2026 | Stifel MAINTAIN | Buy |
| Oct 13, 2026 | TD Cowen MAINTAIN | Hold |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Saxonov Serge Chief Executive Officer Nov 10, 2026 | SELL | $1.9M |
SULIMAN SHEHNAAZ Director Sep 22, 2026 | SELL | $48.8K |
SULIMAN SHEHNAAZ Director Sep 22, 2026 | SELL | $22.8K |
SULIMAN SHEHNAAZ Director Sep 22, 2026 | SELL | $107.1K |
SULIMAN SHEHNAAZ Director Sep 22, 2026 | SELL | $185.4K |
SULIMAN SHEHNAAZ Director Sep 22, 2026 | SELL | $100.5K |
Saxonov Serge Chief Executive Officer Sep 22, 2026 | SELL | $159.2K |
Saxonov Serge Chief Executive Officer Sep 22, 2026 | SELL | $78.2K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.04 | -$0.04–-$0.04 | -700.0% | $178.6M |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
28 filings · 1 bullish · 7 bearish · 3 mixed · 17 neutral- NEUTRAL SC 13G/ANov 16, 2026
T. Rowe Price Associates filed an amended Schedule 13G for 10x Genomics, reporting a 14.5% passive stake as of September 30, 2026, up from the prior 5.22% stake held by ARK Investment Management. The increase in stake is a routine passive update with no change in investment intent.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 3Nov 6, 2026
Ansuman Satpathy filed a Form 3 initial statement of beneficial ownership with the SEC, reporting…
This is a routine initial ownership disclosure for a new insider. Monitor future Form 4 filings for any open-market purchases or grants that could signal insider conviction.
- NEUTRAL 3Nov 6, 2026
Joseph E. Gilliam filed a Form 3 initial statement of beneficial ownership, reporting 31 shares of…
This is a standard initial ownership filing for a new insider. No trading signal; monitor future Form 4 filings for any material transactions by Gilliam.
- BULLISH 8-KNov 5, 2026
10x Genomics reported Q3 2026 revenue of $150.7M (+1% YoY), slightly above the $147.8M consensus…
The raised guidance and Atera commercial launch are the key catalysts. Monitor Atera adoption and consumables pull-through in Q4; the raised midpoint implies ~$630M for FY2026, above the prior $620M…
All TXG filing & press-release reports (28)
- SC 13G/A reportNov 16, 2026
- 3 reportNov 6, 2026
- 3 reportNov 6, 2026
- 8-K reportNov 5, 2026
- PRESS-RELEASE reportNov 5, 2026
- 8-K reportNov 2, 2026
- INST-CLUSTER reportOct 23, 2026
- SC 13G/A reportOct 7, 2026
- CLUSTER reportSep 24, 2026
- 144 reportSep 22, 2026
- CLUSTER reportSep 11, 2026
- 144 reportSep 3, 2026
- CLUSTER reportAug 28, 2026
- CLUSTER reportAug 26, 2026
- COURT-RULING reportAug 19, 2026
- INST-CLUSTER reportAug 19, 2026
- CLUSTER reportAug 17, 2026
- INST-CLUSTER reportJul 5, 2026
- 144 reportJun 16, 2026
- CLUSTER reportMay 27, 2026
- DEFA14A reportApr 24, 2026
- CLUSTER reportFeb 23, 2026
- CLUSTER reportFeb 23, 2026
- CLUSTER reportFeb 23, 2026
- CLUSTER reportFeb 23, 2026
- CLUSTER reportFeb 23, 2026
- CLUSTER reportFeb 23, 2026
- CLUSTER reportFeb 23, 2026